Literature DB >> 24027431

TBK1 regulates prostate cancer dormancy through mTOR inhibition.

Jin Koo Kim1, Younghun Jung, Jingcheng Wang, Jeena Joseph, Anjali Mishra, Elliott E Hill, Paul H Krebsbach, Kenneth J Pienta, Yusuke Shiozawa, Russell S Taichman.   

Abstract

The mechanisms that regulate hematopoietic stem cell (HSC) dormancy and self-renewal are well established and are largely dependent on signals emanating from the HSC niche. Recently, we found that prostate cancer (PCa) cells target the HSC niche in mouse bone marrow (BM) during metastasis. Little is known, however, as to how the HSC niche may regulate dormancy in cancer cells. In this study, we investigated the effects of TANK binding kinase 1 (TBK1) on PCa dormancy in the BM niche. We found that binding with niche osteoblasts induces the expression of TBK1 in PCa cells PC3 and C4-2B. Interestingly, TBK1 interacts with mammalian target of rapamycin (mTOR) and inhibits its function. Rapamycin, an mTOR inhibitor, induces cell cycle arrest of PCa cells and enhances chemotherapeutic resistance of PCa cells. As a result, the knockdown of TBK1 decreases PCa stem-like cells and drug resistance in vitro and in vivo. Taken together, these results strongly indicate that TBK1 plays an important role in the dormancy and drug resistance of PCa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24027431      PMCID: PMC3769885          DOI: 10.1593/neo.13402

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  56 in total

1.  Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence.

Authors:  Salomé González-Reyes; Jesús M Fernández; Luis O González; Alina Aguirre; Aurelio Suárez; José M González; Safwan Escaff; Francisco J Vizoso
Journal:  Cancer Immunol Immunother       Date:  2010-10-27       Impact factor: 6.968

Review 2.  Balancing dormant and self-renewing hematopoietic stem cells.

Authors:  Anne Wilson; Elisa Laurenti; Andreas Trumpp
Journal:  Curr Opin Genet Dev       Date:  2009-10-05       Impact factor: 5.578

3.  The Lkb1 metabolic sensor maintains haematopoietic stem cell survival.

Authors:  Sushma Gurumurthy; Stephanie Z Xie; Brinda Alagesan; Judith Kim; Rushdia Z Yusuf; Borja Saez; Alexandros Tzatsos; Fatih Ozsolak; Patrice Milos; Francesco Ferrari; Peter J Park; Orian S Shirihai; David T Scadden; Nabeel Bardeesy
Journal:  Nature       Date:  2010-12-02       Impact factor: 49.962

Review 4.  mTOR: from growth signal integration to cancer, diabetes and ageing.

Authors:  Roberto Zoncu; Alejo Efeyan; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12-15       Impact factor: 94.444

5.  mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.

Authors:  Kazuko Matsumoto; Tokuzo Arao; Kaoru Tanaka; Hiroyasu Kaneda; Kanae Kudo; Yoshihiko Fujita; Daisuke Tamura; Keiichi Aomatsu; Tomohide Tamura; Yasuhide Yamada; Nagahiro Saijo; Kazuto Nishio
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

6.  mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging.

Authors:  Rogerio M Castilho; Cristiane H Squarize; Lewis A Chodosh; Bart O Williams; J Silvio Gutkind
Journal:  Cell Stem Cell       Date:  2009-09-04       Impact factor: 24.633

7.  Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.

Authors:  Jessica E Hutti; Rhine R Shen; Derek W Abbott; Alicia Y Zhou; Kam M Sprott; John M Asara; William C Hahn; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-05-14       Impact factor: 17.970

8.  Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells.

Authors:  Daisuke Nakada; Thomas L Saunders; Sean J Morrison
Journal:  Nature       Date:  2010-12-02       Impact factor: 49.962

9.  Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells.

Authors:  Boyi Gan; Jian Hu; Shan Jiang; Yingchun Liu; Ergün Sahin; Li Zhuang; Eliot Fletcher-Sananikone; Simona Colla; Y Alan Wang; Lynda Chin; Ronald A Depinho
Journal:  Nature       Date:  2010-12-02       Impact factor: 49.962

10.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors:  David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

View more
  54 in total

Review 1.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 2.  Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.

Authors:  Maroof Hasan; Nan Yan
Journal:  Pharmacol Res       Date:  2016-06-25       Impact factor: 7.658

3.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

4.  The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.

Authors:  Jeanine L Van Nostrand; Alice Brisac; Stephano S Mello; Suzanne B R Jacobs; Richard Luong; Laura D Attardi
Journal:  Cancer Discov       Date:  2015-03-26       Impact factor: 39.397

Review 5.  The biology and clinical implications of prostate cancer dormancy and metastasis.

Authors:  Colm Morrissey; Robert L Vessella; Paul H Lange; Hung-Ming Lam
Journal:  J Mol Med (Berl)       Date:  2015-10-21       Impact factor: 4.599

Review 6.  The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.

Authors:  Hung-Ming Lam; Robert L Vessella; Colm Morrissey
Journal:  Drug Discov Today Technol       Date:  2014-03

7.  Chronic innate immune activation of TBK1 suppresses mTORC1 activity and dysregulates cellular metabolism.

Authors:  Maroof Hasan; Vijay K Gonugunta; Nicole Dobbs; Aktar Ali; Guillermo Palchik; Maria A Calvaruso; Ralph J DeBerardinis; Nan Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

8.  The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists.

Authors:  Cagri Bodur; Dubek Kazyken; Kezhen Huang; Bilgen Ekim Ustunel; Kate A Siroky; Aaron Seth Tooley; Ian E Gonzalez; Daniel H Foley; Hugo A Acosta-Jaquez; Tammy M Barnes; Gabrielle K Steinl; Kae-Won Cho; Carey N Lumeng; Steven M Riddle; Martin G Myers; Diane C Fingar
Journal:  EMBO J       Date:  2017-11-17       Impact factor: 11.598

9.  Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow.

Authors:  Eunsohl Lee; Ann M Decker; Frank C Cackowski; Lulia A Kana; Kenji Yumoto; Younghun Jung; Jingcheng Wang; Laura Buttitta; Todd M Morgan; Russell S Taichman
Journal:  J Cell Biochem       Date:  2016-09-26       Impact factor: 4.429

10.  Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.

Authors:  Ha Linh Vu; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2014-06-24       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.